Endovascular Treatment of Intracranial Atherosclerotic StenosisArtikel in mehreren Sprachen: English | deutsch
11. September 2018
25. Januar 2019
04. April 2019 (online)
Background Intracranial atherosclerotic stenosis (ICAS) causes 5 – 10 % of all ischemic strokes in the European population. Indication for endovascular treatment is a special challenge and the selection of material as well as interventional techniques essentially differs from the treatment of extracranial stenoses. According to recent studies patient selection became evidence based; however the method should not be abandoned. New technical approaches can contribute to avoid complications.
Method We performed a review of the literature with regard to conservative as well as endovascular treatment of ICAS. Different technical approaches are discussed and strategies to avoid complications are stressed. Based on the treatment indication, the positions of the authorities and the professional societies are taken into account.
Results and Conclusion A single self-expanding stent is approved for the treatment of ICAS. Balloon mounted and other self-expanding Stents are available for off-label use. Anatomical conditions and features of the stenosis determine the choice of material. Distal wire perforations causing intracranial bleedings may occur during exchange manoeuvres and constitute one of the technical complications in the treatment of ICAS. In contrast, there is hardly any efficient way to eliminate the risk of ischemia in the territory of perforating arteries arising from the intracranial posterior circulation and the middle cerebral artery. The results of the randomized prospective trials strengthen the conservative treatment of ICAS. Endovascular treatment should not be withheld from patients with either hemodynamic stenosis, recurrent ischemic events under best medical treatment in the territory of the stenosed vessel or acute occlusions of a stenosis.
Medical therapy and risk reduction constitute the primary treatment of intracranial stenosis.
Recurrence under best medical treatment and acute occlusions of intracranial stenosis are indications for endovascular treatment.
Acute occlusions due to intracranial stenosis often are treated by stenting and angioplasty after mechanical thrombectomy.
Exchange manoeuvres with distal wire perforation can cause intracranial hemorrhage.
Basal ganglia and brain stem ischemia constitute a specific risk in treatment of vessel segments bearing perforators.
Nordmeyer H, Chapot R, Haage P. Endovascular Treatment of Intracranial Atherosclerotic Stenosis. Fortschr Röntgenstr 2019; 191: 643 – 652
- 1 Feigin VL, Forouzanfar MH, Krishnamurthi R. et al. Global and regional burden of stroke during 1990–2010: findings from the Global Burden of Disease Study 2010. Lancet 2014; 383: 245-254
- 2 Wang Y, Zhao X, Liu L. et al. Prevlence and outcomes of symptomatic intracranial large artery stenoses and occlusions in China: the Chinese Intracranial Atherosclerosis (CICAS) Study. Stroke 2014; 45: 663-669
- 3 Suri MFK, Qiao Y, Ma X. et al. Prevalence of Intracranial Atherosclerotic Stenosis Using High-Resolution Magnetic Resonance Angiography in the General Population: The Atherosclerosis Risk in Communities Study. Stroke 2016; 47: 1187-1193
- 4 Caplan LR. Intracranial branch atheromatous disease: a neglected, understudied, and underused concept. Neurology 1989; 39: 1246-1250
- 5 Holmstedt CA, Turan TN, Chimowitz MI. Atherosclerotic intracranial arterial stenosis: risk factors, diagnosis, and treatment. Lancet Neurol 2013; 12: 1106-1114
- 6 Kim JS, Nah HW, Park SM. et al. Risk factors and stroke mechanisms in atherosclerotic stroke: intracranial compared with extracranial and anterior compared with posterior circulation disease. Stroke 2012; 43: 3313-3318
- 7 Kern R, Steinke W, Daffertshofer M. et al. Stroke recurrences in patients with symptomatic vs asymptomatic middle cerebral artery disease. Neurology 2005; 65: 859-864
- 8 Kasner SE, Chimowitz MI, Lynn MJ. et al. Predictors of Ischemic Stroke in the Territory of a Symptomatic Intracranial Arterial Stenosis. Circulation 2006; 113: 555-563
- 9 Mazighi M, Tanasescu R, Ducrocq X. et al. Prospective study of symptomatic atherothrombotic intracranial stenoses: the GESICA study. Neurology 2006; 66: 1187-1191
- 10 Powers WJ, Clarke WR, Grubb RL. et al. Extracranial-Intracranial Bypass Surgery for Stroke Prevention in Hemodynamic Cerebral Ischemia: The Carotid Occlusion Surgery Study: A Randomized Trial. JAMA J Am Med Assoc 2011; 306: 1983-1992
- 11 The SSYLVIA Study Investigators. Stenting of Symptomatic Atherosclerotic Lesions in the Vertebral or Intracranial Arteries (SSYLVIA): Study Results. Stroke 2004; 35: 1388-1392
- 12 Bose A, Hartmann M, Henkes H. et al. A Novel, Self-Expanding, Nitinol Stent in Medically Refractory Intracranial Atherosclerotic Stenoses: The Wingspan Study. Stroke 2007; 38: 1531-1537
- 13 Costalat V, Maldonado IL, Vendrell JF. et al. Endovascular treatment of symptomatic intracranial stenosis with the Wingspan stent system and Gateway PTA balloon: a multicenter series of 60 patients with acute and midterm results. J Neurosurg 2011; 115: 686-693
- 14 Costalat V, Maldonado IL, Zerlauth JB. et al. Endovascular treatment of symptomatic intracranial arterial stenosis: six-year experience in a single-center series of 42 consecutive patients with acute and mid-term results. Neurosurgery 2010; 67: 1505-1513 ; discussion 1513–1514
- 15 Gandini R, Chiaravalloti A, Pampana E. et al. Intracranial atheromatous disease treatment with the Wingspan stent system: evaluation of clinical, procedural outcome and restenosis rate in a single-center series of 21 consecutive patients with acute and mid-term results. Clin Neurol Neurosurg 2013; 115: 741-747
- 16 Chimowitz MI, Lynn MJ, Derdeyn CP. et al. Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med 2011; 365: 993-1003
- 17 Zaidat OO, Fitzsimmons BF, Woodward BK. et al. Effect of a Balloon-Expandable Intracranial Stent vs Medical Therapy on Risk of Stroke in Patients With Symptomatic Intracranial Stenosis: The VISSIT Randomized Clinical Trial. JAMA 2015; 313: 1240
- 18 Alexander M. WEAVE: Positive Phase 4 Results for Intracranial Stenting. Int. Stroke Conf. ISC 2018 Late-Break. Abstr. 13 Present. January 25 2018o. J.
- 19 Genton E, Barnett HJ, Fields WS. et al. XIV. Cerebral ischemia: the role of thrombosis and of antithrombotic therapy. Study group on antithrombotic therapy. Stroke 1977; 8: 150-175
- 20 Chimowitz MI, Lynn MJ, Howlett-Smith H. et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med 2005; 352: 1305-1316
- 21 Jung JM, Kang DW, Yu KH. et al. Predictors of Recurrent Stroke in Patients With Symptomatic Intracranial Arterial Stenosis. Stroke 2012; 43: 2785-2787
- 22 Markus HS, Droste DW, Kaps M. et al. Dual Antiplatelet Therapy With Clopidogrel and Aspirin in Symptomatic Carotid Stenosis Evaluated Using Doppler Embolic Signal Detection: The Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) Trial. Circulation 2005; 111: 2233-2240
- 23 Fox KAA, Mehta SR, Peters R. et al. Benefits and Risks of the Combination of Clopidogrel and Aspirin in Patients Undergoing Surgical Revascularization for Non–ST-Elevation Acute Coronary Syndrome: The Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. Circulation 2004; 110: 1202-1208
- 24 Steinhubl SR, Berger PB, Iii JTM. et al. Early and Sustained Dual Oral Antiplatelet Therapy Following Percutaneous Coronary Intervention: A Randomized Controlled Trial. JAMA 2002; 288: 2411-2420
- 25 Wang Y, Zhao X, Lin J. et al. Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack. JAMA 2016; 316: 70-78
- 26 Schömig A. Ticagrelor – Is There Need for a New Player in the Antiplatelet-Therapy Field?. N Engl J Med 2009; 361: 1108-1111
- 27 Johnston SC, Amarenco P, Albers GW. et al. Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack. N Engl J Med 2016; 375: 35-43
- 28 Efficacy and safety of ticagrelor versus aspirin in acute stroke or transient ischaemic attack of atherosclerotic origin: a subgroup analysis of SO... – PubMed – NCBI. o. J.
- 29 Akbari SH, Reynolds MR, Kadkhodayan Y. et al. Hemorrhagic complications after prasugrel (Effient) therapy for vascular neurointerventional procedures. J Neurointerventional Surg 2013; 5: 337-343
- 30 Kwon SU, Cho YJ, Koo JS. et al. Cilostazol Prevents the Progression of the Symptomatic Intracranial Arterial Stenosis: The Multicenter Double-Blind Placebo-Controlled Trial of Cilostazol in Symptomatic Intracranial Arterial Stenosis. Stroke 2005; 36: 782-786
- 31 Kwon SU, Hong KS, Kang DW. et al. Efficacy and safety of combination antiplatelet therapies in patients with symptomatic intracranial atherosclerotic stenosis. Stroke 2011; 42: 2883-2890
- 32 Leung TW. Evolution of intracranial atherosclerotic disease under modern medical therapy. – PubMed – NCBI. o. J.
- 33 Nordmeyer H, Chapot R, Aycil A. et al. Angioplasty and Stenting of Intracranial Arterial Stenosis in Perforator-Bearing Segments: A Comparison Between the Anterior and the Posterior Circulation. Front Neurol 2018; 9: 533
- 34 Qureshi AI, Chaudhry SA, Siddiq F. et al. A randomized trial comparing primary angioplasty versus stent placement for symptomatic intracranial stenosis. J Vasc Interv Neurol 2013; 6: 34-41
- 35 Jiang WJ, Srivastava T, Gao F. et al. Perforator stroke after elective stenting of symptomatic intracranial stenosis. Neurology 2006; 66: 1868-1872
- 36 Aycil A, Weber R, Chapot R. et al. Comparison of periprocedural complications and long-term outcome of intracranial angioplasty alone or with stenting of perforator-bearing arteries in the anterior and posterior circulation. Eur Stroke J 2017; 2: 09-034
- 37 Park S, Kim JH, Kwak JK. et al. Intracranial stenting for severe symptomatic stenosis: self-expandable versus balloon-expandable stents. Interv Neuroradiol J Peritherapeutic Neuroradiol Surg Proced Relat Neurosci 2013; 19: 276-282
- 38 Vajda Z, Schmid E, Güthe T. et al. The modified Bose method for the endovascular treatment of intracranial atherosclerotic arterial stenoses using the Enterprise stent. Neurosurgery 2012; 70: 91-101 ; discussion 101
- 39 Jiang WJ, Cheng-Ching E, Abou-Chebl A. et al. Multicenter Analysis of Stenting in Symptomatic Intracranial Atherosclerosis. Neurosurgery 2012; 70: 25-31
- 40 Groschel K, Schnaudigel S, Pilgram SM. et al. A Systematic Review on Outcome After Stenting for Intracranial Atherosclerosis. Stroke 2009; 40: e340-e347
- 41 Jiang WJ, Du B, Hon SFK. et al. Do patients with basilar or vertebral artery stenosis have a higher stroke incidence poststenting?. J Neurointerventional Surg 2010; 2: 50-54
- 42 Derdeyn CP, Fiorella D, Lynn MJ. et al. Mechanisms of Stroke After Intracranial Angioplasty and Stenting in the SAMMPRIS Trial. Neurosurgery 2013; 72: 777-795
- 43 Li TX, Gao BL, Cai DY. et al. Wingspan Stenting for Severe Symptomatic Intracranial Atherosclerotic Stenosis in 433 Patients Treated at a Single Medical Center. PLoS ONE 2015; 10: e0139377
- 44 Di Lorenzo E, Sauro R, Varricchio A. et al. Benefits of drug-eluting stents as compared to bare metal stent in ST-segment elevation myocardial infarction: four year results of the PaclitAxel or Sirolimus-Eluting stent vs bare metal stent in primary angiOplasty (PASEO) randomized trial. Am Heart J 2009; 158: e43-e50
- 45 Stone GW, Lansky AJ, Pocock SJ. et al. Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. N Engl J Med 2009; 360: 1946-1959
- 46 Costa MA, Simon DI. Molecular basis of restenosis and drug-eluting stents. Circulation 2005; 111: 2257-2273
- 47 Park S, Lee D, Chung WJ. et al. Long-term Outcomes of Drug-eluting Stents in Symptomatic Intracranial Stenosis. Neurointervention 2013; 8: 9-14
- 48 Qureshi AI, Kirmani JF, Hussein HM. et al. Early and intermediate-term outcomes with drug-eluting stents in high-risk patients with symptomatic intracranial stenosis. Neurosurgery 2006; 59: 1044-1051
- 49 Gruber P, Garcia-Esperon C, Berberat J. et al. Neuro Elutax SV drug-eluting balloon versus Wingspan stent system in symptomatic intracranial high-grade stenosis: a single-center experience. J NeuroInterventional Surg 2018; DOI: neurintsurg-2017-013699.
- 50 Kurre W, Aguilar-Pérez M, Fischer S. et al. Solving the Issue of Restenosis After Stenting of Intracranial Stenoses: Experience with Two Thin-Strut Drug-Eluting Stents (DES)–Taxus ElementTM and Resolute IntegrityTM . Cardiovasc Intervent Radiol 2015; 38: 583-591
- 51 Möhlenbruch MA, Pfaff J, Herweh C. et al. One-pass endovascular treatment of intracranial atherosclerotic stenosis with a novel PTA balloon and self-expanding microstent. Neuroradiology 2016; 58: 893-899
- 52 Thomalla G. ASSISTENT – Register: Ein Zwischenstand – Technische Herausforderungen und klinische Relevanz. o. J.
- 53 Abou-Chebl A, Steinmetz H. Critique of „Stenting Versus Aggressive Medical Therapy for Intracranial Arterial Stenosis“ by Chimowitz et al. in the New England Journal of Medicine. Stroke 2012; 43: 616-620
- 54 Chimowitz MI, Fiorella D, Derdeyn CP. et al. Response to Critique of the Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) Trial by Abou-Chebl and Steinmetz. Stroke 2012; 43: 2806-2809
- 55 IQWiG. Rapid Report N14-01, o. J.
- 56 Fiehler J. Studies in Intracranial Stenting: We Must Not Retire from the Game of Science. Clin Neuroradiol 2014; 24: 309-311
- 57 Kurre W, Berlis A, Diener HC. et al. IQWiG Arbeitspapier GA15-02: „Stents zur Behandlung intrakranieller Stenosen: VISSIT Studie und Akutbehandlung in Deutschland“. Clin Neuroradiol 2015; 25: 445-449
- 58 G-BA. Einsatz von Stents zur Behandlung intrakranieller Gefäßstenosen weitgehend ausgeschlossen – Gemeinsamer Bundesausschuss. o. J.
- 59 FDA. Food and Drug Administration. FDA safety communication: narrowed indications for use for the Wingspan Stent System. August 8, 2012. o. J.